Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000485380 | SCV000566920 | pathogenic | not provided | 2015-07-06 | criteria provided, single submitter | clinical testing | The W1169X nonsense variant in the USH2A gene is predicted to cause loss of normal protein functioneither through protein truncation or nonsense-mediated mRNA decay. Although this variant has not beenreported previously to our knowledge, we interpret it as pathogenic. |
Counsyl | RCV000674309 | SCV000799624 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-05-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003449188 | SCV004182335 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003449187 | SCV004182336 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000485380 | SCV004292961 | pathogenic | not provided | 2023-09-25 | criteria provided, single submitter | clinical testing | This variant is present in population databases (no rsID available, gnomAD 0.007%). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 419244). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 26969326). This sequence change creates a premature translational stop signal (p.Trp1169*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |